Researchers at the Johns Hopkins Kimmel Cancer Center have developed a new liquid biopsy test that can be used to predict risk of early disease progression in women with metastatic breast cancer. This could help oncologists by optimizing the use of available and effective therapies with the goal of achieving better clinical outcomes and prolonging survival. Read more about the study here.
